Spuriously raised serum creatinine associated with an excipient present in an intravenous dexamethasone formulation

Annals of Clinical Biochemistry

Volumn 49, Issue 3, 2012, Pages 292-294

  Darby, Denise ^a   So, June ^a   Russell, Joanne ^a   Monaghan, Phillip J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEXAMETHASONE; EXCIPIENT; ONDANSETRON; POTASSIUM; SODIUM; UREA;

ACCURACY; ARTICLE; BLOOD SAMPLING; CANNULA; CASE REPORT; CREATININE BLOOD LEVEL; DRUG FORMULATION; HAND; HUMAN; LUNG CANCER; LUNG METASTASIS; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; UREA BLOOD LEVEL; VEIN PUNCTURE;

CHEMISTRY, PHARMACEUTICAL; CREATININE; DEXAMETHASONE; EXCIPIENTS; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE;

EID: 84861502506     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011114     Document Type: Article

References (5)

1. Akers MJ. Excipient-drug interactions in parenteral formulations. J Pharm Sci 2002;91:2283-300
2. The International Pharmaceutical Excipients Council. The IPEC Excipient Composition Guide 2009. See http://www.ipec-europe.org/UPLOADS/IPECCompositionGuidefinal.pdf (last checked 13 July 2011)
3. Dexamethasone 3.3 mg/ml Solution for Injection (vial). See http://emc.medicines.org.uk/medicine/23141/SPC/Dexamethasone (last checked 4 November 2010)
4. DiPiro JT, Spruill WJ, Blouin RA, Pruemer JM, Wade WE. Concepts in Clinical Pharmacokinetics. 4th edn. Bethesda, MD: American Society of Health-System Pharmacists, Inc, 2005
5. United States Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products. See http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (last checked 13 July 2011)